» Articles » PMID: 33264090

RNF41 Regulates the Damage Recognition Receptor Clec9A and Antigen Cross-presentation in Mouse Dendritic Cells

Abstract

The dendritic cell receptor Clec9A facilitates processing of dead cell-derived antigens for cross-presentation and the induction of effective CD8 T cell immune responses. Here, we show that this process is regulated by E3 ubiquitin ligase RNF41 and define a new ubiquitin-mediated mechanism for regulation of Clec9A, reflecting the unique properties of Clec9A as a receptor specialized for delivery of antigens for cross-presentation. We reveal RNF41 is a negative regulator of Clec9A and the cross-presentation of dead cell-derived antigens by mouse dendritic cells. Intriguingly, RNF41 regulates the downstream fate of Clec9A by directly binding and ubiquitinating the extracellular domains of Clec9A. At steady-state, RNF41 ubiquitination of Clec9A facilitates interactions with ER-associated proteins and degradation machinery to control Clec9A levels. However, Clec9A interactions are altered following dead cell uptake to favor antigen presentation. These findings provide important insights into antigen cross-presentation and have implications for development of approaches to modulate immune responses.

Citing Articles

Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials.

Hussain Z, Zhang Y, Qiu L, Gou S, Liu K NPJ Vaccines. 2025; 10(1):27.

PMID: 39920156 PMC: 11806010. DOI: 10.1038/s41541-025-01084-2.


Role of Ubiquitin Signaling in Modulating Dendritic Cell Function.

Jie Z Adv Exp Med Biol. 2024; 1466:101-111.

PMID: 39546138 DOI: 10.1007/978-981-97-7288-9_7.


Single-shot dendritic cell targeting SARS-CoV-2 vaccine candidate induces broad, durable and protective systemic and mucosal immunity in mice.

Cheang N, Tan K, Tan P, Purushotorma K, Yap W, Tullett K Mol Ther. 2024; 32(7):2299-2315.

PMID: 38715364 PMC: 11286822. DOI: 10.1016/j.ymthe.2024.05.003.


A Simple and Rapid Protocol for the Isolation of Murine Bone Marrow Suitable for the Differentiation of Dendritic Cells.

Song R, Bafit M, Tullett K, Tan P, Lahoud M, OKeeffe M Methods Protoc. 2024; 7(2).

PMID: 38525778 PMC: 10961764. DOI: 10.3390/mps7020020.


Mapping the tumor microenvironment in clear cell renal carcinoma by single-cell transcriptome analysis.

Wang Y, Wang Y, Liu B, Gao X, Li Y, Li F Front Genet. 2023; 14:1207233.

PMID: 37533434 PMC: 10392130. DOI: 10.3389/fgene.2023.1207233.


References
1.
Venereau E, Ceriotti C, Bianchi M . DAMPs from Cell Death to New Life. Front Immunol. 2015; 6:422. PMC: 4539554. DOI: 10.3389/fimmu.2015.00422. View

2.
Grotzke J, Cresswell P . Are ERAD components involved in cross-presentation?. Mol Immunol. 2015; 68(2 Pt A):112-5. DOI: 10.1016/j.molimm.2015.05.002. View

3.
Huysamen C, Willment J, Dennehy K, Brown G . CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3+ dendritic cells and a subset of monocytes. J Biol Chem. 2008; 283(24):16693-701. PMC: 2562446. DOI: 10.1074/jbc.M709923200. View

4.
Tullett K, Leal Rojas I, Minoda Y, Tan P, Zhang J, Smith C . Targeting CLEC9A delivers antigen to human CD141 DC for CD4 and CD8T cell recognition. JCI Insight. 2016; 1(7):e87102. PMC: 5033826. DOI: 10.1172/jci.insight.87102. View

5.
Ahrens S, Zelenay S, Sancho D, Hanc P, Kjaer S, Feest C . F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity. 2012; 36(4):635-45. DOI: 10.1016/j.immuni.2012.03.008. View